Aeterna Zentaris claims it booted CEO and then discovered a plot to grab control of its lead asset
A few weeks after Aeterna Zentaris’ lead drug Zoptrex flopped in a Phase III trial of endometrial cancer, the board and the CEO at the biotech were engaged in a brutal internal battle. On July 20, CEO David Dodd was booted for failing to carry out the “express directives” of the board, the company says. And about a week later, Aeterna general counsel Philip Theodore followed him out the exit.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
